Could a simple scan predict breast cancer drug success?

NCT ID NCT06909604

Recruiting now Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new PET imaging method that uses a radioactive tracer to spot HER2 proteins on breast cancer cells. The goal is to see if the scan can predict how well patients will respond to antibody-drug conjugate therapy. Researchers will enroll 50 adults with HER2-positive or low tumors who are receiving neoadjuvant therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Al18F-HER2-BCH (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors predict which breast cancer patients will benefit from antibody-drug conjugate therapy, avoiding ineffective treatments.
What could go wrong: This is an early-stage imaging study with only 50 participants, so results may not apply to all patients. The tracer's ability to predict response is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Peking University Cancer Hospital & Institute
RECRUITING

Beijing, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.